• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

    8/5/23 8:13:00 PM ET
    $EQRX
    $NEWR
    $RETA
    $RVMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $EQRX alert in real time by email

    NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) --

    EQRx, Inc. (NASDAQ:EQRX)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote.

    If you are an EQRX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Revolution Medicines, Inc. (NASDAQ:RVMD)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRx, Inc. to RVMD. Under the terms of the proposed merger, EQRx, Inc. shareholders will receive the number of shares of RVMD stock equal to the sum of ~7.69M RVMD shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average RVMD share price measured in close proximity to the stockholder vote.

    If you are a RVMD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    New Relic, Inc. (NYSE:NEWR)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of NEWR to Francisco Partners and TPG Inc. for $87.00 per share in cash for each share of NEWR common stock owned.

    If you are a NEWR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of RETA to Biogen Inc. for $172.50 per share in cash for each share of RETA common stock owned.

    If you are a RETA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: [email protected]



    Get the next $EQRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EQRX
    $NEWR
    $RETA
    $RVMD

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    11/3/2025$77.00Outperform
    RBC Capital Mkts
    Revolution Medicines Inc.
    $RVMD
    10/21/2025$90.00Outperform
    Mizuho
    Revolution Medicines Inc.
    $RVMD
    10/16/2025$85.00Buy
    Stifel
    Revolution Medicines Inc.
    $RVMD
    9/12/2025$72.00Strong Buy
    Raymond James
    Revolution Medicines Inc.
    $RVMD
    9/5/2025$99.00Buy
    Truist
    Revolution Medicines Inc.
    $RVMD
    8/19/2025$75.00Overweight
    Piper Sandler
    Revolution Medicines Inc.
    $RVMD
    8/15/2025$67.00Overweight
    Wells Fargo
    Revolution Medicines Inc.
    $RVMD
    7/15/2025$65.00Buy
    Goldman
    More analyst ratings

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Kelsey Stephen Michael exercised 25,000 shares at a strike of $4.73 and sold $1,213,540 worth of shares (25,000 units at $48.54) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    10/15/25 5:09:49 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    General Counsel Cislini Jeff sold $79,624 worth of shares (1,799 units at $44.26), decreasing direct ownership by 3% to 50,425 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    9/26/25 4:13:13 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Wei Lin sold $98,982 worth of shares (2,160 units at $45.82), decreasing direct ownership by 2% to 88,339 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    9/18/25 4:39:39 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    SEC Filings

    View All

    SEC Form 10-Q filed by Revolution Medicines Inc.

    10-Q - Revolution Medicines, Inc. (0001628171) (Filer)

    11/5/25 4:10:04 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Revolution Medicines, Inc. (0001628171) (Filer)

    11/5/25 4:00:25 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Revolution Medicines Inc.

    SCHEDULE 13G - Revolution Medicines, Inc. (0001628171) (Subject)

    11/5/25 11:44:45 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

    Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity

    2/28/23 5:14:09 PM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Revolution Medicines with a new price target

    RBC Capital Mkts initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $77.00

    11/3/25 9:08:29 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Revolution Medicines with a new price target

    Mizuho initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $90.00

    10/21/25 7:22:03 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel resumed coverage on Revolution Medicines with a new price target

    Stifel resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $85.00

    10/16/25 8:28:24 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this yearDaraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug Designation and a Commissioner's National Priority VoucherNew leadership appointments strengthened global development and commercialization capabilitiesRevolution Medicines to hold webcast today at 4:30 p

    11/5/25 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Participate in November 2025 Investor Conferences

    REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in two upcoming investor conferences. Details of the company's participation are as follows: Guggenheim 2nd Annual Healthcare Innovation Conference Fireside Chat: Tuesday, November 11 at 9:00 a.m. ET Jefferies Global Healthcare Conference Fireside Chat: Tuesday, November 18 at 9:30 a.m. GMT To listen to a live webcast of any of these events, or access archived

    11/4/25 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

    REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live

    10/29/25 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Leadership Updates

    Live Leadership Updates

    View All

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

    Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research and development functions. "The team and I are excited to welcome Rajiv to Reata. His previous experience and his proven track record will help position the company for future growth," said Warren Huff, Chief Executive Officer. "His le

    6/13/23 6:45:00 AM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Relic Expands Technology Partner Ecosystem with Over 100 Integrations

    New Relic integration ecosystem grows 25% to date in 2022, with additions from leading cloud services, open source tools, and enterprise technologies; appoints new VP of product partnerships to accelerate mature observability practices for engineering teams across all verticals and use cases New Relic (NYSE:NEWR), the all-in-one observability platform for every engineer, announced it has expanded its partner ecosystem to help organizations mature their observability practices. The company has grown its technology partner ecosystem by over 25% to date in 2022, and now offers integrations with 500+ cloud services, open source tools, and enterprise technologies to empower every engineer to st

    12/15/22 9:00:00 AM ET
    $NEWR
    Computer Software: Prepackaged Software
    Technology

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Financials

    Live finance-specific insights

    View All

    Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this yearDaraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug Designation and a Commissioner's National Priority VoucherNew leadership appointments strengthened global development and commercialization capabilitiesRevolution Medicines to hold webcast today at 4:30 p

    11/5/25 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

    REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live

    10/29/25 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

    Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasibCompany entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercializationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicte

    8/6/25 4:02:29 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EQRX
    $NEWR
    $RETA
    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    11/8/24 10:52:39 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/14/24 6:30:27 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/14/24 9:26:21 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care